Detalhe da pesquisa
1.
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.
Hepatology
; 66(6): 1814-1825, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28741307
2.
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Appl Health Econ Health Policy
; 16(5): 711-722, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30039348